

RESULTS OF ANNUAL GENERAL MEETING

MELBOURNE (AUSTRALIA) 26 November 2025: In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions put to shareholders of Invion Limited (ASX: IVX) ("**Invion**") at its 2025 Annual General Meeting held earlier today.

This announcement was approved for release by the Company Secretary of Invion Limited.

Investor and Media enquiries:

Thian Chew (Chairman & CEO)

T: +61 3 9692 7222

E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)

M: +61 409 341 613

E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX).

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".

Invin Limited
2025 Annual General Meeting
Wednesday, 26 November 2025
Results of Meeting

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution Details			Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Results
Resolution		Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1.	Adoption of Remuneration Report	Ordinary	1,060,618 83.77%	100,969 7.97%	104,612 8.26%	1,609 -	1,482,596 93.62%	100,969 6.38%	2,609 -	Carried
2.	Re-election of Mr Alistair Bannallack as a Director of the Company	Ordinary	1,345,955 92.36%	6,696 0.46%	104,612 7.18%	5,000 -	7,472,658 99.91%	6,696 0.09%	5,000 -	Carried
3(a).	Issue of unlisted Options to previous Director	Ordinary	1,169,680 84.03%	117,556 8.45%	104,612 7.52%	26,013 -	6,978,017 98.34%	117,556 1.66%	27,013 -	Carried
3(b).	Issue of unlisted Options to Mr Alexander Murray	Ordinary	1,169,680 81.44%	161,958 11.28%	104,612 7.28%	26,013 -	6,978,017 97.73%	161,958 2.27%	27,013 -	Carried
3(c).	Issue of unlisted Options to Mr Alex Berecz	Ordinary	1,169,680 81.44%	161,958 11.28%	104,612 7.28%	26,013 -	7,295,383 97.83%	161,958 2.17%	26,013 -	Carried
3(d).	Issue of Shares and Listed Options to the Lead Manager	Ordinary	1,169,860 81.44%	161,958 11.28%	104,612 7.28%	25,833 -	7,295,383 97.83%	161,958 2.17%	25,833 -	Carried
4.	Adoption of Executive and Employee Share Option Plan	Ordinary	1,032,543 79.12%	167,808 12.86%	104,612 8.02%	7,247 -	1,454,521 89.66%	167,808 10.34%	7,247 -	Carried
5.	Ratification of prior issue of Convertible Notes	Ordinary	1,181,781 81.77%	148,911 10.30%	114,612 7.93%	16,959 -	7,317,484 98.01%	148,911 1.99%	16,959 -	Carried
6.	Approval of 10% Placement Facility	Special	1,195,880 81.79%	161,532 11.05%	104,612 7.16%	239 -	7,321,583 97.84%	161,532 2.16%	239 -	Carried

*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.